AI Engines For more Details: Perplexity Kagi Labs You
Schizophrenia: Clozapine is considered one of the most effective medications for the treatment of schizophrenia, particularly for individuals with treatment-resistant schizophrenia (TRS). It helps alleviate positive symptoms of schizophrenia such as hallucinations, delusions, and thought disorders, as well as negative symptoms such as social withdrawal, apathy, and blunted affect. Clozapine may also improve cognitive function and overall functioning in individuals with schizophrenia.
Bipolar Disorder: Clozapine may be used off-label in the management of bipolar disorder, particularly in cases where other medications have been ineffective or poorly tolerated. It may help stabilize mood and reduce the frequency and severity of manic and depressive episodes in individuals with bipolar disorder. Clozapine may be particularly useful in cases of bipolar disorder with psychotic features or treatment-resistant symptoms.
Suicidal Behavior: Clozapine has been shown to reduce the risk of suicidal behavior in individuals with schizophrenia or bipolar disorder, particularly in those with a history of suicide attempts or high suicide risk. It may help reduce suicidal ideation, impulsive behavior, and aggression, thereby improving overall safety and well-being in affected individuals.
Dosage and Administration: Clozapine is typically administered orally in the form of tablets or orally disintegrating tablets (ODTs). The dosage and frequency of clozapine therapy depend on factors such as the specific psychiatric diagnosis being treated, the severity of symptoms, the individual patient's response to treatment, and any concurrent medications or medical conditions. Clozapine therapy usually begins with a low initial dose that is gradually titrated upward based on clinical response and tolerability.
Side Effects: Clozapine therapy may be associated with a range of potential side effects, some of which can be serious or life-threatening. Common side effects may include sedation, dizziness, dry mouth, constipation, weight gain, metabolic changes (such as elevated blood sugar and lipid levels), and anticholinergic effects (such as blurred vision and urinary retention). Rare but serious side effects of clozapine may include agranulocytosis (a severe decrease in white blood cell count), myocarditis, seizures, and metabolic syndrome. Patients should be closely monitored for side effects during clozapine therapy, and regular blood tests are required to monitor white blood cell counts and metabolic parameters.
Contraindications and Precautions: Clozapine is contraindicated in individuals with a history of clozapine-induced agranulocytosis or severe hypersensitivity reactions to clozapine. It should be used with caution in patients with cardiovascular disease, seizures, diabetes, or other medical conditions that may increase the risk of adverse effects. Clozapine may interact with other medications, particularly those that affect the central nervous system or prolong the QT interval, increasing the risk of adverse effects or drug interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| ADHD | 1.3 | 1.3 | |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.4 | -3 |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.6 | |
| Allergies | 0.6 | 1.9 | -2.17 |
| Allergy to milk products | 0.3 | 0.5 | -0.67 |
| Alzheimer's disease | 0.9 | 1.8 | -1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.5 | 1.2 | 0.25 |
| Ankylosing spondylitis | 0.8 | 0.1 | 7 |
| Anorexia Nervosa | 0.4 | 0.6 | -0.5 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.2 | 1 |
| Asthma | 1 | 2.2 | -1.2 |
| Atherosclerosis | 0 | 0.6 | 0 |
| Atrial fibrillation | 0.9 | 1.1 | -0.22 |
| Autism | 3.1 | 3.5 | -0.13 |
| Barrett esophagus cancer | 0 | 0.1 | 0 |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 0.7 | 0.1 | 6 |
| Brain Trauma | 0.2 | -0.2 | |
| Carcinoma | 0.9 | 0.5 | 0.8 |
| Celiac Disease | 0.4 | 1.1 | -1.75 |
| Cerebral Palsy | 0.6 | 0.2 | 2 |
| Chronic Fatigue Syndrome | 0.8 | 1 | -0.25 |
| Chronic Kidney Disease | 0.6 | 0.7 | -0.17 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.1 | 3 |
| Chronic Urticaria (Hives) | 0.5 | 1.3 | -1.6 |
| Coagulation / Micro clot triggering bacteria | 1.3 | 0.3 | 3.33 |
| Colorectal Cancer | 0.9 | 0.3 | 2 |
| Constipation | 0.2 | 0.1 | 1 |
| Coronary artery disease | 0.3 | 0.3 | |
| COVID-19 | 3.7 | 3.8 | -0.03 |
| Crohn's Disease | 1.6 | 1.7 | -0.06 |
| cystic fibrosis | 0.3 | 0.2 | 0.5 |
| deep vein thrombosis | 0.8 | 0.3 | 1.67 |
| Depression | 2 | 4 | -1 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.1 | 0.2 | -1 |
| Endometriosis | 0.9 | 0.9 | |
| Eosinophilic Esophagitis | 0 | 0 | |
| Epilepsy | 0.8 | 2.6 | -2.25 |
| Fibromyalgia | 1.3 | 0.5 | 1.6 |
| Functional constipation / chronic idiopathic constipation | 1.8 | 0.7 | 1.57 |
| gallstone disease (gsd) | 0.5 | 0.1 | 4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0.1 | 0 |
| Generalized anxiety disorder | 0.3 | 0.1 | 2 |
| giant cell arteritis | 0 | 0 | |
| Glioblastoma | 0.1 | -0.1 | |
| Graves' disease | 0.5 | 0.1 | 4 |
| Halitosis | 0.1 | 0.1 | 0 |
| Hashimoto's thyroiditis | 0.7 | 0.2 | 2.5 |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.7 | 0.3 | 1.33 |
| hypercholesterolemia (High Cholesterol) | 0 | 1 | 0 |
| hyperglycemia | 0.1 | 1.9 | -18 |
| Hyperlipidemia (High Blood Fats) | 0.5 | 0.5 | |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 1.2 | 1.2 | 0 |
| Hypoxia | 0.9 | 0.9 | |
| IgA nephropathy (IgAN) | 1 | -1 | |
| Inflammatory Bowel Disease | 0.5 | 3 | -5 |
| Insomnia | 0.2 | 0.2 | 0 |
| Intelligence | 0 | 0.4 | 0 |
| Intracranial aneurysms | 0.5 | 0.5 | |
| Irritable Bowel Syndrome | 1.7 | 2 | -0.18 |
| Liver Cirrhosis | 2 | 1 | 1 |
| Long COVID | 1.7 | 1.2 | 0.42 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.2 | 1 | -4 |
| ME/CFS with IBS | 0.2 | 0.1 | 1 |
| ME/CFS without IBS | 0.3 | 0.1 | 2 |
| Menopause | 0.5 | 0.5 | |
| Metabolic Syndrome | 1.8 | 2.6 | -0.44 |
| Mood Disorders | 3.2 | 4 | -0.25 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 2.4 | 1.8 | 0.33 |
| Multiple system atrophy (MSA) | 2 | 2 | |
| Neuropathy (all types) | 0.6 | 0.1 | 5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 1.7 | -1.83 |
| Obesity | 1.8 | 1.9 | -0.06 |
| obsessive-compulsive disorder | 1.7 | 1.7 | 0 |
| Osteoarthritis | 0.3 | 0.3 | |
| Osteoporosis | 0.2 | 1 | -4 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 2.3 | 0.7 | 2.29 |
| Polycystic ovary syndrome | 0.6 | 0.6 | 0 |
| Postural orthostatic tachycardia syndrome | 0 | 0 | |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0 | 0 | |
| Psoriasis | 1.3 | 1.9 | -0.46 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.9 | 0.3 | 5.33 |
| Rosacea | 0.2 | -0.2 | |
| Schizophrenia | 1.7 | 0.2 | 7.5 |
| scoliosis | 0.2 | -0.2 | |
| Sjögren syndrome | 1 | 0.8 | 0.25 |
| Sleep Apnea | 0 | 0.2 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
| Stress / posttraumatic stress disorder | 1.3 | 1.2 | 0.08 |
| Systemic Lupus Erythematosus | 0.9 | 0.1 | 8 |
| Tic Disorder | 0.4 | -0.4 | |
| Tourette syndrome | 0.5 | 0.1 | 4 |
| Type 1 Diabetes | 0.8 | 0.3 | 1.67 |
| Type 2 Diabetes | 1.8 | 2.5 | -0.39 |
| Ulcerative colitis | 0.6 | 3.1 | -4.17 |
| Unhealthy Ageing | 0.8 | 1.2 | -0.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.